High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma

Blood Cancer Journal

Volumn 7, Issue 8, 2017, Pages

  Mills, J R ^a   Barnidge, D R ^a   Dispenzieri, A ^a   Murray, D L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; M PROTEIN; GLYCOPROTEIN; PROTEIN M (GLYCOPROTEIN);

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLONE; FEMALE; HUMAN; LIGHT CHAIN; MALE; MASS SPECTROMETRY; MEASUREMENT; MOLECULAR WEIGHT; MONOCLONAL IMMUNOGLOBULIN RAPID ACCURATE MASS MEASUREMENT; MULTIPLE MYELOMA; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; STRINGENT COMPLETE RESPONSE; TREATMENT RESPONSE; AUTOGRAFT; BLOOD; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

ADULT; AGED; AUTOGRAFTS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 85028453373     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2017.75     Document Type: Article

References (18)

1. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801-1809.
2. Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279-3287.
3. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085.
4. Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 2009; 114: 2617-2618.
5. Gonsalves WI, Gertz MA, Dispenzieri A, Lacy MQ, Lin Y, Singh PP et al. Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood 2013; 122: 1746-1749.
6. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcia-Larana J et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118: 529-534.
7. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114: 3139-3146.
8. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073-3079.
9. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540-2547.
10. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e346.
11. Paiva B, Puig N, Garcia-Sanz R, San Miguel JF. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res 2015; 21: 2001-2008.
12. Barnidge DR, Tschumper RC, Theis JD, Snyder MR, Jelinek DF, Katzmann JA et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res 2014; 13: 1905-1910.
13. Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA et al. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteomics Clin Appl 2014; 8: 783-795.
14. Bergen HR 3rd, Dasari S, Dispenzieri A, Mills JR, Ramirez-Alvarado M, Tschumper RC et al. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem 2016; 62: 243-251.
15. Barnidge DR, Dasari S, Botz CM, Murray DH, Snyder MR, Katzmann JA et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res 2014; 13: 1419-1427.
16. Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016; 62: 1334-1344.
17. Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol 2017; 92: 772-779.
18. Kendrick F, Evans ND, Arnulf B, Avet-Loiseau H, Decaux O, Dejoie T et al. Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma. Front Physiol 2017; 8: 149.